On Friday, iRhythm Technologies received an upgrade to its Relative Strength (RS) Rating, from 76 to 83.
IBD's unique RS Rating identifies technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners often have an RS Rating of over 80 as they begin their biggest runs.
Hone Your Stock-Picking Skills By Focusing On These Factors
While iRhythm Technologies is not near a proper buying range right now, see if it manages to form and break out from a proper base.
The company posted 0% EPS growth last quarter. Sales gains came in at 18%.
The company holds the No. 22 rank among its peers in the Medical-Services industry group. Castle Biosciences, NeoGenomics and Hims & Hers Health are among the top 5 highly rated stocks within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
